|
GB8529014D0
(en)
|
1985-11-25 |
1986-01-02 |
Biogen Nv |
Enhanced secretion of heterologous proteins
|
|
WO1987005330A1
(en)
|
1986-03-07 |
1987-09-11 |
Michel Louis Eugene Bergh |
Method for enhancing glycoprotein stability
|
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5571714A
(en)
|
1988-12-22 |
1996-11-05 |
Celtrix Pharmaceuticals, Inc. |
Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
|
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
|
ZA914750B
(en)
|
1990-06-20 |
1992-03-25 |
Bristol Myers Squibb Co |
Methods of modulating blood pressure using tgf-beta and antagonists thereof
|
|
GB9106678D0
(en)
|
1991-03-28 |
1991-05-15 |
Ferguson Mark W J |
Wound healing
|
|
JP4124815B2
(ja)
|
1991-10-31 |
2008-07-23 |
ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ |
ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
|
|
US6008011A
(en)
|
1991-10-31 |
1999-12-28 |
Whitehead Institute For Biomedical Research |
TGF-β type II receptor cDNAs
|
|
US5543143A
(en)
|
1992-03-06 |
1996-08-06 |
Corixa Corporation |
Method for activating macrophages/monocytes
|
|
WO1994009815A1
(en)
|
1992-10-29 |
1994-05-11 |
Celtrix Pharmaceuticals, Inc. |
USES OF TGF-β RECEPTOR FRAGMENT AS A THERAPEUTIC AGENT
|
|
US5677196A
(en)
|
1993-05-18 |
1997-10-14 |
University Of Utah Research Foundation |
Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
CA2174098C
(en)
|
1993-10-14 |
2011-01-25 |
Douglas A. Melton |
Method of inducing and maintaining neuronal cells
|
|
US5470952A
(en)
|
1993-10-20 |
1995-11-28 |
Regeneron Pharmaceuticals, Inc. |
CNTF and IL-6 antagonists
|
|
US5525490A
(en)
|
1994-03-29 |
1996-06-11 |
Onyx Pharmaceuticals, Inc. |
Reverse two-hybrid method
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
US5814565A
(en)
|
1995-02-23 |
1998-09-29 |
University Of Utah Research Foundation |
Integrated optic waveguide immunosensor
|
|
US5866323A
(en)
|
1995-04-07 |
1999-02-02 |
Case Western Reserve University |
Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
|
|
NZ306767A
(en)
|
1995-04-11 |
2000-03-27 |
Univ Johns Hopkins |
Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
|
|
US6423501B2
(en)
|
1996-12-13 |
2002-07-23 |
Beth Israel Deaconess Medical Center |
Calcium-independent negative regulation by CD81 of receptor signaling
|
|
PT975771E
(pt)
|
1997-04-18 |
2007-10-01 |
Biogen Idec Inc |
Proteínas de fusão da região constante da imunoglobulina/receptor do ftc-beta do tipoii
|
|
AU7467898A
(en)
|
1997-04-21 |
1998-11-13 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
|
|
US6294350B1
(en)
|
1997-06-05 |
2001-09-25 |
Dalhousie University |
Methods for treating fibroproliferative diseases
|
|
ZA988461B
(en)
|
1997-09-18 |
1999-03-30 |
Idec Pharma Corp |
Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
|
|
PT1068241E
(pt)
|
1998-04-02 |
2007-11-19 |
Genentech Inc |
Variantes de anticorpos e respectivos fragmentos
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
AU4572899A
(en)
|
1998-06-16 |
2000-01-05 |
Biogen, Inc. |
Variant type ii tgf-beta receptor fusion proteins and methods
|
|
ES2146552B1
(es)
|
1998-11-24 |
2001-04-16 |
Inst Cientifico Tecnol Navarra |
Peptidos inhibidores de tgf/31
|
|
DK1263464T3
(da)
|
2000-03-09 |
2013-01-28 |
Genzyme Corp |
Anvendelse af antagonist anti-TGF-BETA-antistoffer til behandling eller til forebyggelse af tab af nyrefunktion
|
|
AU2001249446A1
(en)
|
2000-03-24 |
2001-10-08 |
Dzgenes, L.L.C. |
Diagnostic polymorphisms of tgf-beta-rii promoter
|
|
US20030028905A1
(en)
|
2001-07-31 |
2003-02-06 |
Petra Knaus |
Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
|
|
WO2003061587A2
(en)
|
2002-01-22 |
2003-07-31 |
Genzyme Corporation |
USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION
|
|
US7919084B2
(en)
|
2002-06-17 |
2011-04-05 |
St. Vincent's Hospital Sydney Limited |
Methods of diagnosis, prognosis and treatment of cardiovascular disease
|
|
WO2004056352A1
(en)
|
2002-12-19 |
2004-07-08 |
Scios, Inc. |
TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-β INHIBITORS
|
|
EP1620128A1
(en)
|
2003-04-30 |
2006-02-01 |
Genzyme Corporation |
Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
AU2004267425B2
(en)
|
2003-08-13 |
2010-10-21 |
The Board Of Trustees Of The University Of Illinois |
Silencing of TGF-beta receptor type II expression by sIRNA
|
|
CA2536293A1
(en)
|
2003-08-22 |
2005-03-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating copd and pulmonary hypertension
|
|
WO2005113585A2
(en)
|
2004-05-20 |
2005-12-01 |
Acceleron Pharma Inc. |
Modified tgf-beta superfamily polypeptides
|
|
US7786261B2
(en)
|
2004-09-02 |
2010-08-31 |
National Research Council Of Canada |
Coiled-coil fusion proteins comprising cell receptor domains
|
|
JP2008513542A
(ja)
|
2004-09-22 |
2008-05-01 |
ジェンザイム・コーポレイション |
免疫抑制剤の腎毒性を制限するためのＴＧＦ−βアンタゴニストの使用
|
|
US7795389B2
(en)
|
2004-09-28 |
2010-09-14 |
The Board Of Regents Of The University Of Texas System |
Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
|
|
WO2006044433A2
(en)
|
2004-10-13 |
2006-04-27 |
The Ohio State University Research Foundation |
Methods to treat or prevent viral-associated lymphoproliferative disorders
|
|
EP1850873B1
(en)
|
2005-02-08 |
2018-11-28 |
Genzyme Corporation |
Antibodies to tgfbeta
|
|
JP5342834B2
(ja)
|
2008-09-05 |
2013-11-13 |
日東電工株式会社 |
骨髄線維症処置剤
|
|
ITMI20060181A1
(it)
|
2006-02-03 |
2007-08-04 |
Univ Padova |
Modulatori del tgf-b e loro uso
|
|
EP2230252A1
(en)
|
2006-03-13 |
2010-09-22 |
The Johns Hopkins University |
Augmentation of endothelial thromboresistance
|
|
WO2007145956A2
(en)
|
2006-06-05 |
2007-12-21 |
Novartis Ag |
USE OF TGF-β ANTAGONISTS IN TREATMENT OF PARATHYROID-RELATED DISORDERS
|
|
MX2009003518A
(es)
|
2006-10-03 |
2009-08-25 |
Genzyme Corp |
Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
|
|
ES2449753T3
(es)
|
2007-03-19 |
2014-03-21 |
National Research Council Of Canada |
Proteínas de fusión que comprenden dos dominios de unión tgf-beta
|
|
EP2171062A1
(en)
|
2007-06-15 |
2010-04-07 |
Genzyme Corporation |
Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
|
|
BRPI0815572A2
(pt)
|
2007-08-22 |
2015-02-18 |
Irm Llc |
Compostos e composições como inibidores de quinases
|
|
US20110245107A1
(en)
|
2008-01-18 |
2011-10-06 |
The Brigham And Women's Hospital, Inc. |
Selective differentiation, identification, amd modulation of human th17 cells
|
|
US20110104121A1
(en)
|
2008-05-21 |
2011-05-05 |
Wira Charles R |
Female Reproductive Tract and Anal Prophylaxes
|
|
WO2009152610A1
(en)
|
2008-06-20 |
2009-12-23 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
|
|
CA2729810A1
(en)
|
2008-07-02 |
2010-01-07 |
Emergent Product Development Seattle, Llc |
Tgf-.beta. antagonist multi-target binding proteins
|
|
EP2326670A4
(en)
|
2008-09-17 |
2014-04-16 |
Nat Res Council Canada |
HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY
|
|
US20120010178A1
(en)
|
2008-10-21 |
2012-01-12 |
President And Fellows Of Harvard College |
Methods and compounds for treatment of neurodegenerative disorders
|
|
WO2010083034A1
(en)
|
2009-01-13 |
2010-07-22 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
|
US20120114640A1
(en)
|
2009-05-08 |
2012-05-10 |
Kulkarni Ashok B |
MODULATION OF THE TGF- ß AND PI3K/AKT PATHWAYS IN THE DIAGNOSIS AND TREATMENT OF SQUAMOUS CELL CARCINOMA
|
|
US20110172296A1
(en)
|
2010-01-12 |
2011-07-14 |
Bennett C Frank |
Modulation of transforming growth factor-beta 1 expression
|
|
JP6066732B2
(ja)
|
2010-03-05 |
2017-01-25 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
標的免疫調節抗体および融合タンパク質に基づく組成物および方法
|
|
CN101852804B
(zh)
|
2010-03-29 |
2013-06-12 |
中国医学科学院病原生物学研究所 |
Gdf15蛋白的抗体的新用途
|
|
US8080568B1
(en)
|
2010-06-29 |
2011-12-20 |
Ewha University - Industry Collaboration Foundation |
2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
|
|
MY165160A
(en)
|
2010-09-01 |
2018-02-28 |
Genzyme Corp |
TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
|
|
US20130287688A1
(en)
|
2010-11-18 |
2013-10-31 |
Xtuit Pharmaceuticals, Inc. |
Novel compositions and uses of anti-hypertension agents for cancer therapy
|
|
US8800906B2
(en)
|
2010-12-27 |
2014-08-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Use of transforming growth factor-beta neutralizing antibodies and fusion proteins thereof in treating pain
|
|
CA2823104A1
(en)
|
2011-01-06 |
2012-07-12 |
Glaxo Group Limited |
Ligands that bind tgf-beta receptor ii
|
|
DK2699602T3
(en)
*
|
2011-04-19 |
2017-06-06 |
Merrimack Pharmaceuticals Inc |
BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES
|
|
CN103781798B
(zh)
|
2011-04-20 |
2018-03-13 |
阿塞勒隆制药公司 |
内皮糖蛋白多肽及其用途
|
|
CN102850458B
(zh)
|
2011-06-28 |
2014-10-01 |
华博生物医药技术（上海）有限公司 |
新型重组双功能融合蛋白及其制法和用途
|
|
WO2013012648A1
(en)
|
2011-07-15 |
2013-01-24 |
Emory University |
Gdf15 in diagnostic and therapeutic applications
|
|
JP2014524417A
(ja)
|
2011-08-01 |
2014-09-22 |
タフツ メディカル センター インコーポレイテッド |
心不全および関連状態の処置
|
|
WO2013059879A1
(en)
|
2011-10-26 |
2013-05-02 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Compositions and methods for the treatment of fibrosis and fibrotic diseases
|
|
PT3489254T
(pt)
|
2012-04-30 |
2022-12-30 |
Biocon Ltd |
Proteínas de fusão direcionadas/imunomoduladoras e seus métodos de fabrico
|
|
AU2013262972A1
(en)
|
2012-05-16 |
2014-12-11 |
Aadigen, Llc |
Multi-target modulation for treating fibrosis and inflammatory conditions
|
|
BR112015021595A2
(pt)
|
2013-03-11 |
2017-10-10 |
Genzyme Corp |
anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno
|
|
AU2014249405C1
(en)
*
|
2013-03-12 |
2018-08-16 |
Biocon Ltd. |
Fusion immunomodulatory proteins and methods for making same
|
|
EP2986636B1
(en)
|
2013-04-17 |
2018-11-14 |
Baylor College Of Medicine |
Immunosuppressive tgf-beta signal converter
|
|
HK1225740A1
(zh)
*
|
2013-08-22 |
2017-09-15 |
Acceleron Pharma Inc. |
TGF-β受体II型变体及其用途
|
|
CN105934249A
(zh)
|
2013-11-21 |
2016-09-07 |
布里格姆及妇女医院股份有限公司 |
用于治疗肺高压的组合物和方法
|
|
SI3105246T1
(sl)
|
2014-02-10 |
2021-11-30 |
Merck Patent Gmbh |
Ciljana inhibicija TGF BETA
|
|
AU2015264519B2
(en)
|
2014-05-18 |
2021-01-28 |
Children's Medical Center Corporation |
Methods and compositions relating to exosomes
|
|
AU2015273097A1
(en)
|
2014-06-13 |
2016-11-17 |
Novartis Ag |
Use of serelaxin to reduce GDF-15
|
|
EP3693004A1
(en)
|
2014-08-01 |
2020-08-12 |
The Brigham and Women's Hospital, Inc. |
An inhibitor of gdf-15 for use in treating fibrosis
|
|
JP6631865B2
(ja)
*
|
2014-08-11 |
2020-01-15 |
日本化薬株式会社 |
ＴＧＦβ阻害機能を持つキメラタンパク質
|
|
MA53400A
(fr)
|
2015-04-06 |
2021-08-04 |
Acceleron Pharma Inc |
Hétéromultimères alk7: actriib et leurs utilisations
|
|
CN113683708A
(zh)
*
|
2015-04-06 |
2021-11-23 |
阿塞勒隆制药公司 |
单臂i型和ii型受体融合蛋白和其用途
|
|
EP3331550B1
(en)
|
2015-08-04 |
2022-11-02 |
Acceleron Pharma Inc. |
Composition for treating myeloproliferative disorders
|
|
EP3344660B1
(en)
|
2015-08-31 |
2025-03-05 |
National Research Council of Canada |
Tgf-beta-receptor ectodomain fusion molecules and uses thereof
|
|
WO2017134592A1
(en)
|
2016-02-03 |
2017-08-10 |
Biocon Limited |
Anti-cd20/immunomodulatory fusion proteins and methods for making same
|
|
SG11201901126UA
(en)
|
2016-08-12 |
2019-03-28 |
Merck Patent Gmbh |
Combination therapy for cancer
|
|
CN118307682A
(zh)
|
2016-09-27 |
2024-07-09 |
埃皮辛特瑞柯斯公司 |
免疫调节性融合蛋白
|
|
WO2018129331A1
(en)
|
2017-01-07 |
2018-07-12 |
Merck Patent Gmbh |
Dosing regimens and dosage forms for targeted tgf-b inhibition
|
|
US11866481B2
(en)
|
2017-03-02 |
2024-01-09 |
National Research Council Of Canada |
TGF-β-receptor ectodomain fusion molecules and uses thereof
|
|
SI3628049T1
(sl)
*
|
2017-05-04 |
2023-10-30 |
Acceleron Pharma Inc. |
Fuzijske beljakovine receptorja TGF-beta tipa II in njihova uporaba
|
|
CA3090538A1
(en)
|
2018-02-09 |
2019-08-15 |
Acceleron Pharma, Inc. |
Methods for treating heterotopic ossification
|